Introduction

Urothelial carcinoma of the bladder (UCB) (1) is the fourth most common cancer in men, and the fifth most common cancer overall according to 2019 statistics reported by the American Cancer Society (1). Approximately 80,470 new cases of UCB (61,700 in men and 18,770 in women) and 17,670 deaths from UCB (12,870 in men and 4,800 in women) are expected in 2019 (1). UCB accounts for approximately 90% of all bladder malignancies (2-4). Although most patients present with non-muscle invasive bladder cancer (NMIBC), approximately 30% of patients present with muscle invasive bladder cancer (MIBC) and that number goes up to 40% when considering patients who progress from NMIBC to MIBC (2-4).

Radical cystectomy (RC) plays a central role in the treatment of UCB (3). It is a mainstay in the management of MIBC, together with peri-operative chemotherapy and appropriate lymphadenectomy, but is also important for the treatment of very high risk and treatment-refractory NMIBC (5-7). RC is one of the most challenging surgical techniques in Urology. Although the first records of RC date back to the 1900s, Marshall and Whitmore were the first to describe the surgical principles of RC in the 1940s. These same techniques have been refined over time, but complication rates and morbidity remain high after RC (8). Minimally invasive techniques including robotic-assisted laparoscopic RC have been developed, but these have not yet significantly impacted outcomes (3).
Surgical techniques

RC entails removal of the bladder, adjacent organs, and regional lymph nodes. In males, it includes the removal of the prostate and the seminal vesicles whereas in females, the reproductive organs (ovaries, fallopian tubes, uterus and anterior vagina) may also be removed to achieve best oncologic outcomes. RC can be distinguished from simple cystectomy in that simple cystectomy is supratrigonal or prostate sparing and often the trigone urothelium along with pelvic lymph nodes is left behind as the bladder is removed. Simple cystectomies are often performed in patients with unrelenting symptoms but not for oncologic control.

Open versus robot assisted RC

Despite advances in technology and patient care, open RC (ORC) still has high rates of perioperative complication and mortality even in the most experienced hands at high volume centers (17). For many abdominal surgeries, the minimally invasive approach is deemed superior with respect to postoperative recovery and peri-operative morbidity without influencing cancer-free rates. With the advent of robotic assisted surgery, there is the potential to improve surgeon precision and dexterity while reducing surgeon fatigue. With this in mind, there have been numerous studies looking to see if robot-assisted RC (RARC) can improve outcomes of this highly morbid surgery. In 2015, Bochner and colleagues reported on a randomized controlled trial comparing ORC and RARC. The trial was closed prematurely at the time of a planned interim analysis when it was apparent that an improvement in the 90-day rate of grade 2–5 complications with RARC (62% RARC vs. 66% ORC) would not be met with further patient enrollment (18). The trial showed decreased blood loss and increased length of surgery, but the length of stay and pathology outcomes were similar and RARC was significantly less cost effective (18).

In the CORAL trial, a single-centre, randomized, controlled three-arm study, Khan and colleagues [2016] aimed to distinguish differences with respect to 30- and 90-day complication rates between laparoscopic (LRC), robotic
and open cystectomy (19). Secondary end points were perioperative clinical, pathologic, and oncologic outcomes, and quality of life (19). Sixty patients were enrolled between 2009 and 2012. The 30-day complication rates were significantly higher in the ORC arm than the LRC arm but there was no significant difference between groups at 90 days (19). Mean operative time was longer in RARC compared with ORC and LRC but there were no significant differences in QoL measures (19). Although the sample size is small in this study, the conclusions do correlate well with the results reported from multiple other non-randomized and retrospective studies.

In the RAZOR trial, Parekh and colleagues randomly assigned 302 patients across 15 US institutions to undergo ORC (n=152) or RARC (n=150) between 2011 and 2014 (20). They demonstrated non-inferiority of RARC [72.3% (95% CI, 64.3 to 78.8)] in comparison to ORC [71.6% (95% CI, 63.6 to 78.2)] with respect to 2-year progression-free survival (20).

A Cochrane review recently analyzed the results of five randomised controlled trials comprising a total of 541 participants managed by ORC (n=270) and RARC (n=271) (21). The primary outcomes included time to recurrence and major complications (Clavien grade 3 to 5). This review concluded that there was little or no difference in oncological outcomes or risk of major complications between RARC and ORC in the treatment of MIBC (21). In this review, they also compared their findings with the findings of other systematic reviews looking at randomized controlled trials and there appeared to be a consensus in the conclusions made by this review and the five other similar studies (21-26). All of these studies were conducted with extracorporeal urinary diversion, which appears to be the key driver of post-operative complications. It remains to be seen if intracorporeal diversion, which is becoming more popular, will change this balance (27). In addition, the robotic platform offers the potential for future technologic enhancements, such as the use of indocyanine green to minimize uretero-enteric strictures, which could lead to more significant improvements in outcomes in the

**Figure 1** Upon diagnosis of non-metastatic, muscle-invasive bladder cancer, the recommendation is for patients to undergo neo-adjuvant chemotherapy (NAC) followed by radical cystectomy and pelvic lymph node dissection (PLND). Surgery alone is offered to patients ineligible for or declining NAC, radical cystectomy (with possible adjuvant chemotherapy). Trimodal therapy (TMT), as part of a bladder-preserving approach, is another option for select patients. However, if TMT fails, radical cystectomy remains an option for salvage therapy. This figure has been adapted from the AUA guidelines for MIBC therapy (2). *, Option for patients with solitary tumors ≤5 cm, absence of hydronephrosis, absence of extensive CIS, good bladder function, or patients who are unfit for or declining cystectomy. #, Cis or MMC/5FU = cisplatin or mitomycin C and 5-fluourouracil.
future (28).

**Pelvic lymph node dissection (PLND)**

PLND has been shown to improve survival and has become a routine element of RC for UCB (29-31). There is, however, still much debate about the optimal extent of PLND for maximal oncologic control. In a meta-analysis by Ku and colleagues [2015], up to 25% of organ-confined MIBC had metastatic deposits within the regional lymph nodes (30). Although an extended PLND could potentially help eradicate this metastatic disease, peri-operative complications and cost may increase with an extended template (31).

The nomenclature describing nodal templates varies across studies. A limited template refers to nodes in the perivesical space and obturator fossa, with the external iliac vein as the lateral border and the obturator nerve along the medial border (32). A “standard” lymphadenectomy is proximally bound by the bifurcation of the common iliac artery, extending laterally to the genitofemoral nerve, medially to the bladder and internal iliac vessels and distally by the circumflex iliac vein (32,33). The extended PLND stretches cephalad to the aortic bifurcation (and sometimes above up to the inferior mesentery artery) and includes the pre-sciatic and presacral nodes (34).

Retrospective studies have compared standard and extended PLND. Dhar and colleagues [2008] showed an increase in node-positive disease after an extended PLND (26%) compared to the limited PNLD group (13%) across two institutions (32). The 5-year recurrence-free survival also increased in the extended PLND cohort as compared to the limited PLND (35% versus 7%) (32). In a similar comparison involving one of these two cohorts, there was no additional advantage to the “super-extended” template extending up to the inferior mesenteric artery (35). Other retrospective studies have also failed to show any benefit to progression-free survival or overall survival with the super-extended PLND (13,35,36).

In several retrospective studies, the number of nodes collected has been associated with improved oncologic outcomes, even in groups who had organ-confined disease with no micrometastatic spread to lymph nodes (31,37,38). There are, however, significant differences in how nodes are counted between institutions and between pathologists, which makes this an imperfect measure (39,40).

A definitive determination of the value of the extended PLND is awaiting the report of a completed phase 3 randomized control trial led by SWOG that randomized >600 patients with MIBC to standard versus extended PLND (41,42). This trial was powered to detect an improvement in 3-year disease-free survival from 55% to 65%. A similar but smaller German trial recently demonstrated no advantage to the extended PLND (43). This study enrolled 401 patients and included also patients with T1 disease. A combined analysis of both trials may be necessary to detect a more subtle difference in oncologic outcome.

**Urinary diversion**

Urinary diversion is a necessary component of RC. Two general categories of diversion can be distinguished: incontinent and continent diversion (44).

Incontinent diversions are more widely used as they are technically easier to perform and are more easily managed by the elderly, frail RC population (44,45). The simplest diversion is the cutaneous ureterostomy, which, however, fell out of favor due to the high risk of stricture of the ostomy sites (46). The advantage of this strategy is the avoidance of a bowel anastomosis, which reduces the risk of complications, especially in patients who may otherwise be marginal for RC. The cutaneous ureterostomy is therefore sometimes still performed in frail patients at select centers (47). Similarly, the ureterosigmoidostomy was a simple method for urinary diversion, but it too has fallen out of favor due to the risk of pyelonephritis and adenocarcinoma at the site of ureteral implantation into the colon (37,38).

Ileal conduits were the benchmark for urinary diversion before continent diversions were described and remain the procedure of choice especially in older patients and patients with significant other comorbidities (46). Reported complication rates with ileal conduits range from 45% at five years to 94% at 15 years and they include renal insufficiency, stomal complications including parastomal hernias and stomal stenosis, urinary tract infections, ureteral obstruction and stone formation (46,48).

The continent diversion is further divided into continent cutaneous diversion and orthotopic neobladder. Absolute contraindications to continent diversion include poor renal function, severe hepatic dysfunction, and significant inflammatory bowel disease (39). Continent diversions have a higher rate of metabolic complications through reabsorption of waste products (49). Relative contraindications include previous pelvic and abdominal
radiation and mental impairment (50). Malignant involvement of the urethra requiring urethrectomy and recurrent urethral strictures represent contraindications for neobladder but not continent cutaneous diversion (50).

Patients with a continent cutaneous diversion (46,51) are committed to lifelong intermittent self-catheterization. With reported daytime and nighttime continence rates of 90% to 98%, this method of reconstruction is associated with a good quality of life post RC in most patients (52,53). Potential complications include stomal stenosis requiring reoperation in as many as 21% of patients (54), and stone formation (46,48,54). This technique is less frequently used with the advent of the orthotopic urinary diversion.

Voiding of the orthotopic neobladder is accomplished via relaxation of the external sphincter combined with the Valsalva maneuver (50,55). Daytime continence rates exceed 85% at high volume centers but do vary between 47% to 100% depending on the definition of continence and the length of follow-up (56-58). Up to 50% of patients have nocturnal incontinence due to loss of physiological storage reflexes. Higher rates of ventral hernias may be observed after neobladder construction due to the use of Valsalva voiding (50). Intermittent self-catheterization after neobladder surgery is required due to incomplete bladder emptying in approximately 4% to 25% of patients based on a meta-analysis of more than 2,000 patients and is significantly more predominant in women (59).

Choosing the type of diversion and reconstruction is a decision that has to be made based on a variety of factors including cancer control and patient comorbidities, as well as surgical suitability, post-operative ability to manage the diversion care, and patient preference (60). Few formal studies have documented a difference in the overall quality of life between incontinent or continent urinary diversion, although all such studies are limited by the simple fact that the patient usually will have selected his or her preference for diversion (61-63). A systematic review of health-related quality of life failed to show a superiority of any of the techniques of urinary diversion in quality of life (64).

**Complications of RC**

RC is associated with relatively high perioperative morbidity and mortality, despite improvements in surgical techniques and peri-operative care (17). The incidence of complications after surgery has been reported to be in the range of 30–70% (49,57,65,66). There is a large number of single center studies that document either surgeon specific or center specific results and a number of national databases which have combined such reported results and those show a consistent trend among centers with regard to morbidity and mortality despite the absence of a formal complication reporting system (17,67).

Complications related to RC can be divided into early and late, with early complications referring to those that occur within 30 days of the operation and late encompassing complications occurring between 30–90 days (17,23,68). Postoperative mortality rates range from 0.8% to up to 3% (23,68,69). Mortality appears to be lower in high-volume academic centers even though the patient population at these centers is enriched for those with more co-morbidities (65).

Knap and colleagues [2004] reported common late complications to include ventral hernia (17%), calculus formation (16%), ureteroenteric strictures (14%) and parastomal hernias (8%). The authors also determined that vitamin B12 deficiency and loss of kidney function were more common in older than younger patients. Fifty percent of patients over 70 years experienced (70). Similarly, 26% of patients over the age of 70 experienced loss of renal function in five-year follow-up as compared to 7% of patients under the age of 70 (70).

Shabsigh and colleagues [2009] provided one of the first systematic reports of post RC complications using the standardized Clavien-Dindo classification. They analysed data from 1,142 consecutive cystectomies between 1995 and 2005 and found that 735 (64%) experienced a complication within 90 days of surgery (17). The majority of these (79%) were grade 1 to 2 and considered to be “minor”. Most patients (58%) had one or more complication within the first 30 days after surgery (17).

The most common complication categories were gastrointestinal (29%), infectious (25%), wound-related (15%), cardiac (11%), and genitourinary (11%); however, this pattern did change from early to the late phase of complications. The most common early all-grade complications were gastrointestinal, infectious and wound-related. This switched to infectious, gastrointestinal and genitourinary in the late phase. It must be noted, however, that in both early and late phase, the most common high-grade complications were genitourinary (17). Similar findings were made in another large series (71).

An important advance in our efforts to reduce peri-operative complications and improve post-operative quality of life has been the implementation of Enhanced Recovery after Surgery (ERAS) pathways that define numerous...
evidence-based standard interventions to be followed from pre-operative education to intra-operative fluid management and post-operative nutrition (72,73). Although the impact of any one element is often uncertain, there is compelling evidence that the cumulation of elements shortens hospitals stays and reduces the rate of complications (74,75).

Going forward, it is important to develop a system of unified reporting with cystectomy-related complications because this data can be used to assess pre-operative risk of individual patients for developing post-cystectomy complications (17,68,76,77). If patients can be optimized pre-operatively or be offered other methods of management if the risk of an operation is prohibitive (16,49,60). Careful patient selection is key to a successful operation.

**Conclusions**

RC plays a central role in the multimodal therapy of patients with high risk NMIBC and MIBC. The negative impact on quality of life and the high rate of peri-operative complications pose important limitations, especially in the context of a disease that affects primarily elderly patients with multiple medical co-morbidities. RC must therefore be viewed as one element of a complex, multidisciplinary treatment plan. Measures to improve outcomes include regionalization of care to high volume centers, the use of ERAS protocols, and technologic advances such as robotic surgery, although this last element has yet to have a major impact on outcomes. Patient selection and the tailoring of the urinary diversion to the patient’s needs are paramount. Level I evidence to direct the use of the extended PLND is eagerly awaited in the near future, and neoadjuvant therapies are likely to evolve with advances in systemic therapy. These are all meaningful strides in the effort to improve patient outcomes.

**Acknowledgments**

None.

**Footnote**

*Conflicts of Interest:* The authors have no conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**References**


36. Stein JP. Lymphadenectomy in bladder cancer: how high is "high enough"? Urol Oncol 2006;24:101097JU0000000000000570.


38. May M, Herrmann E, Bolenz C, et al. Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients...


Cite this article as: Aminoltejari K, Black PC. Radical cystectomy: a review of techniques, developments and controversies. Transl Androl Urol 2020. doi: 10.21037/tau.2020.03.23